Trials / Completed
CompletedNCT04830345
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Non-inferiority, Phase 3 Clinical Trial to Compare the Efficacy and Safety of ATGC-100 Versus Botox in Subjects With Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 290 (actual)
- Sponsor
- EuBiologics Co.,Ltd · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ATGC-100 100U | Clostridium botulinum toxin type A |
| BIOLOGICAL | Botox 100U | Clostridium botulinum toxin type A |
Timeline
- Start date
- 2020-06-29
- Primary completion
- 2021-09-01
- Completion
- 2021-10-01
- First posted
- 2021-04-05
- Last updated
- 2022-04-04
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04830345. Inclusion in this directory is not an endorsement.